Healthcare Industry News: La Jolla Pharmaceutical Company
News Release - May 25, 2011
NanoBio(R) Appoints Peter Ulrich to Board of DirectorsANN ARBOR, Mich.--(Healthcare Sales & Marketing Network)-- NanoBio Corporation today announced the appointment of Peter Ulrich, co-founder of TargeGen, to its Board of Directors.
Ulrich most recently served as President and CEO of TargeGen, co-founding the company and leading it from inception through exit in a $560 million acquisition by sanofi-aventis. TargeGen developed small molecule kinase inhibitors for oncology, inflammatory disease, eye disease, myeloproliferative disease, leukemia and other hematological disorders.
“Peter’s business acumen, leadership skills and industry knowledge have led to the growth and success of many companies resulting in significant licensing agreements, private equity investments and M&A activity,” said James R. Baker, MD, CEO and founder of NanoBio. “His insight and expertise will help guide NanoBio as we move our nanoemulsion-based treatments and vaccines towards commercialization and look to develop additional strategic partnerships. Peter will be an asset to our distinguished board.”
Ulrich has more than 35 years of executive experience in biotechnology and healthcare, with more than 20 years of CEO tenure. Prior to co-founding TargeGen, Ulrich was President and CEO of Avia Technology Partners, a biotechnology-oriented, strategic, consulting firm. Ulrich has held positions with Baxter Health Care, La Jolla Pharmaceutical Company, MedClone, Inc., NeuroVir Therapeutics Inc., LipoGen, Inc., BIOTX, Analytical Luminescence Laboratory and The University of Alabama at Birmingham Research Foundation.
Ulrich’s entrepreneurial achievements include a consistent track record of success with early stage life sciences companies, the ability to secure over $150M in private equity financing from venture capital sources and recognition by Ernst & Young as an Entrepreneur of the Year.
NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat® technology platform. The company’s lead product candidates are treatments for herpes labialis (licensed to GSK in the U.S. and Canada), onychomycosis, acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.